Markers of bone metabolism in eugonadal female patients with β-thalassemia major

被引：11

作者：

Angelopoulos, Nicholas G. ^{[1
]}

Goula, Anastasia ^{[2
]}

Katounda, Eugenia ^{[1
]}

Rombopoulos, Grigorios ^{[1
]}

Kaltzidou, Victoria ^{[1
]}

Kaltsas, Dimitrios ^{[1
]}

Konstandelou, Evangellia ^{[3
]}

Tolis, George ^{[1
]}

机构：

[1] Hippokrateion Hosp Athens, Endocrine Dept, Athens, Greece

[2] Childrens Univ Hosp, Athens, Greece

[3] Gen Hosp Piraeus, Hormonal Lab, Piraeus, Greece

来源：

PEDIATRIC HEMATOLOGY AND ONCOLOGY | 2007年 / 24卷 / 5-8期

关键词：

beta-thalassemia; bone turnover; OPG/sRANKL system; osteoporosis;

D O I：

10.1080/08880010701533611

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Osteoprotegerin (OPG) and receptor activator of NF-kappa B ligand (RANKL) have been recently implicated in the pathogenesis of various types of osteoporosis. The aim of this study was to investigate bone turnover in eugonadal female patients with this disease and characterize the possible role of the OPG/RANKL system in thalassemia-related bone loss. Markers of bone turnover and bone mineral density (BMD) zvere measured in 16 eugonadal young females with beta-thalassemia major and 18 age- and sex-matched healthy controls. Bone turnover was significantly increased in thalassemic patients compared to controls but OPG was significantly higher in healthy subjects. BMD values negatively correlated with urine markers of bone resorption but not with OPG/RANKL system.

引用

页码：481 / 491

页数：11

共 27 条

[1]

Serum osteoprotegerin and its ligand in Paget's disease of bone -: Relationship to disease activity and effect of treatment with bisphosphonates [J].

Alvarez, L ;

Peris, P ;

Guañabens, N ;

Vidal, S ;

Ros, I ;

Pons, F ;

Filella, X ;

Monegal, A ;

Muñoz-Gomez, J ;

Ballesta, AM .

ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :824-828

[2]

THE CONTRIBUTION OF HYPOGONADISM TO THE DEVELOPMENT OF OSTEOPOROSIS IN THALASSEMIA MAJOR - NEW THERAPEUTIC APPROACHES [J].

ANAPLIOTOU, MLG ;

KASTANIAS, IT ;

PSARA, P ;

EVANGELOU, EA ;

LIPARAKI, M ;

DIMITRIOU, P .

CLINICAL ENDOCRINOLOGY, 1995, 42 (03) :279-287

[3]

Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].

Browner, WS ;

Lui, LY ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637

[4]

Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis [J].

Buzi, F ;

Maccarinelli, G ;

Guaragni, B ;

Ruggeri, F ;

Radetti, G ;

Meini, A ;

Mazzolari, E ;

Cocchi, D .

CLINICAL ENDOCRINOLOGY, 2004, 60 (01) :87-91

[5]

Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major [J].

Carmina, E ;

Di Fede, G ;

Napoli, N ;

Renda, G ;

Vitale, G ;

Lo Pinto, C ;

Bruno, D ;

Malizia, R ;

Rini, GB .

CALCIFIED TISSUE INTERNATIONAL, 2004, 74 (01) :68-71

[6]

Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine [J].

DeSanctis, V ;

Pinamonti, A ;

DiPalma, A ;

Sprocati, M ;

Atti, G ;

Gamberini, MR ;

Vullo, C .

EUROPEAN JOURNAL OF PEDIATRICS, 1996, 155 (05) :368-372

[7]

Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability [J].

Hannon, R ;

Blumsohn, A ;

Naylor, K ;

Eastell, R .

JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (07) :1124-1133

[8]

Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies normal controls [J].

Haynes, DR ;

Barg, E ;

Crotti, TN ;

Holding, C ;

Weedon, H ;

Atkins, GJ ;

Zannetino, A ;

Ahern, MJ ;

Coleman, M ;

Roberts-Thomson, PJ ;

Kraan, M ;

Tak, PP ;

Smith, MD .

RHEUMATOLOGY, 2003, 42 (01) :123-134

[9]

Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women [J].

Hofbauer, LC ;

Schoppet, M ;

Schüller, P ;

Viereck, V ;

Christ, M .

CLINICAL ENDOCRINOLOGY, 2004, 60 (02) :214-219

[10]

The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases [J].

Hofbauer, LC ;

Heufelder, AE .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2355-2363

← 1 2 3 →